Nephrogenic systemic fibrosis

F1000 Medicine Reports

Volumn 2, Issue 1, 2010, Pages

  Braverman, Irwin M ^a   Cowper, Shawn ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; GADOLINIUM; IMATINIB; IMMUNOSUPPRESSIVE AGENT; LIGAND; NILOTINIB; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PENTOXIFYLLINE; PHOSPHATE; RAPAMYCIN; SODIUM THIOSULFATE; STEROID;

ARTICLE; CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; ENDOTHELIUM INJURY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY FAILURE; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PH; PHOSPHATE BLOOD LEVEL; PLASMAPHERESIS; PUVA; RENAL REPLACEMENT THERAPY; ULTRAVIOLET A RADIATION;

EID: 78650451092     PISSN: None     EISSN: 17575931     Source Type: Journal    
DOI: 10.3410/M2-84     Document Type: Article

References (18)

1. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE: Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001, 23:383-93.
2. The International Center for Nephrogenic Systemic Fibrosis Research (ICNSFR). [http://www.icnsfr.org]
3. Kuo PH, Kanal E, Abu-Alfa A, Cowper SE: Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007, 242:647-9.
4. US Food and Drug Administration - Gadolinium-based Contrast Agents: Class Labeling Change - Risk of Nephrogenic Systemic Fibrosis. [http://www.fda.gov/ Safety/MedWatch/Safety Information/SafetyAlertsforHumanMedicalProducts/ ucm225375.htm]
5. Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA: Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment-report of 33 cases. Radiology 2009, 250:371-7.
6. Kay J: Treatment of nephrogenic systemic fibrosis: update on imatinab mesylate. Presented at Fourth Annual Symposium on Nephrogenic Systemic Fibrosis and Gadolinium-based Contrast Agents. 14-15 May 2010. New York, NY: NY Academy of Sciences; 2010.
7. High WA, Ayers RA, Cowper SE: Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007, 56:710-2.
8. George SJ, Webb SM, Abraham JL, Cramer SP: Synchrotron X-ray analyses demonstrate phosphate-bound gadolinium in skin in nephrogenic systemic fibrosis. Br J Dermatol 2010, 163:1077-81.
9. Edward M, Quinn JA, Mukherjee S, Jensen MB, Jardine AG, Mark PB, Burden AD: Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008, 214:584-93. F1000 Factor 6 Evaluated by Irwin Braverman 29 Sep 2010
10. Edward M, Jardine A, Quinn J, Burden D, Newton B: Effect of gadolinium-based contrast agents on fibroblasts: a possible link to nephrogenic systemic fibrosis. Presented at Fourth Annual Symposium on Nephrogenic Systemic Fibrosis and Gadoliniumbased Contrast Agents. 14-15 May 2010. New York, NY: NY Academy of Sciences; 2010.
11. Bucala R: Circulating fibrocytes:a cellular basis for NSF. J Am Coll Radiol 2008, 5:36-9.
12. Bucala R: Impact of GBCA on fibrocyte function. X-ray analysis demonstrates phosphate-bound Gd in skin in nephrogenic systemic fibrosis. Presented at Fourth Annual Symposium on Nephrogenic Systemic Fibrosis and Gadolinium-based Contrast Agents. 14-15 May 2010. New York, NY: NY Academy of Sciences; 2010.
13. Pietsch H, Sieber MA: The Bayer Schering Pharma AG experience. Presented at Fourth Annual Symposium on Nephrogenic Systemic Fibrosis and Gadolinium-based Contrast Agents. 14-15 May 2010. New York, NY: NY New Academy of Sciences; 2010.
14. Idée J-M. GBCA structures and physiochemical properties (Guerbet). Presented at Fourth Annual Symposium on Nephrogenic Systemic Fibrosis and Gadolinium-based Contrast Agents. 14-15 May 2010. New York, NY: NY Academy of Sciences; 2010.
15. Nicholas SB. The role of osteopontin in fibrosis. Presented at Fourth Annual Symposium on Nephrogenic Systemic Fibrosis and Gadolinium-based Contrast Agents. 14-15 May 2010. New York, NY: NY Academy of Sciences; 2010.
16. Cox A: The Array Biopharma experience. Presented at Fourth Annual Symposium on Nephrogenic Systemic Fibrosis and Gadolinium- based Contrast Agents. 14-15 May 2010. New York, NY: NY Academy of Sciences; 2010.
17. Abu-Alfa A: The impact of NSF on the care of patients with kidney disease. J Am Coll Radiol 2008, 5:45-52.
18. Abu-Alfa A: Approach to the use of GBCA in patients with kidney disease. Presented at Fourth Annual Symposium on Nephrogenic Systemic Fibrosis and Gadolinium-based Contrast Agents. 14-15 May 2010. New York, NY: NY Academy of Sciences; 2010.